Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Vehicle-Controlled, Double-Blind, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of B244 Delivered as an Intranasal Spray for Preventive Treatment in Subjects With Episodic Migraine

NCT03488563 is registered in ClinicalTrials.gov with AOBiome LLC as lead sponsor.

NCT NCT03488563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03488563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Vehicle-Controlled, Double-Blind, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of B244 Delivered as an Intranasal Spray for Preventive Treatment in Subjects With Episodic Migraine
Lead sponsor
AOBiome LLC
Phase
Phase 2
Overall status
Completed
Start date
March 30, 2018
Completion date
July 16, 2019
Enrollment
313 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

migraine